Economic Evaluations for Dementia Interventions

By Melike Belenli Gümüş

June 3, 2024

Introduction

Dementia presents a significant global healthcare challenge, impacting millions and straining resources. By 2050, the number of individuals affected is projected to reach 139 million. The economic burden is substantial, with costs expected to triple by 2030. Despite available treatments, access barriers persist. Economic evaluations for dementia interventions play a crucial role in resource allocation decisions, offering insights into intervention effectiveness.

Twenty-three studies with the majority being cost-utility analyses were comprised within the scope of a review. The included studies, which were conducted from February 2018 to August 2022, underwent quality assessment using the Philips checklist and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 checklist. Various interventions were covered, including pharmacological, non-pharmacological, prevention, diagnostic, and integrated strategies. Markov transition models were commonly employed, with several interventions reported as cost-effective. However, the quality of reporting in the Methods and Results sections was suboptimal in most studies, highlighting areas for improvement in methodology and reporting standards.

Diversifying Intervention Approaches

While pharmacological treatments have been the focus, non-pharmacological strategies are also gaining recognition. However, research bias towards pharmacological interventions remains, highlighting the need for a balanced approach. Incorporating long-term outcomes and considering early-stage interventions are vital for comprehensive dementia management.

Global Disparities and Model Structures

Studies predominantly focus on high-income countries, indicating a need for broader geographical representation. Markov models are commonly used due to the chronic nature of dementia, with limited utilization of discrete-event simulation (DES) models. Transparent reporting of model assumptions and validation processes is essential for reliable results.

Addressing Methodological Gaps

Engaging stakeholders, including patients and caregivers, in model development enhances relevance and acceptance. While societal perspectives are crucial for comprehensive evaluations, their inclusion remains limited. Clear characterization of health states and consideration of multi-attribute measures are essential for accurate assessments.

Utility Measurement Challenges

Utility measurement methods lack detailed reporting, impacting the reliability of comparisons. The use of EQ-5D values is prevalent but may not capture the full spectrum of dementia-related health impacts. Incorporating condition-specific measures and distinguishing between self and proxy reports can enhance assessment accuracy.

Conclusions

This review provides valuable insights into model-based economic evaluations for dementia interventions, highlighting areas for improvement in methodology and reporting standards. By addressing existing gaps and methodological weaknesses, future studies can contribute significantly to optimizing dementia management strategies globally.

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.